Sanofi bumps stake in Regeneron to 22.5%

Sanofi ($SNY) CEO Chris Viehbacher is often pressed to answer why he doesn't just buy Regeneron ($REGN), a biotech outfit closely bonded with Big Pharma on several important development initiatives. So far, Viehbacher insists that the collaborative relationship is ideal, and he's underscored his appreciation for Regeneron by highlighting the big stake Sanofi has in Regeneron stock. Today, that stake got bigger. According to a filing with the SEC, Sanofi has snapped up $71 million worth of Regeneron stock, bumping its stake to 22.5%. Filing

Suggested Articles

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Vertex is keeping mum on exact details but, as with the rest of its biopharma peers, is seeing trial disruption due to the COVID-19 pandemic.

Companies including Novartis and Pfizer are contributing to the joint response through actions including the sharing of proprietary compounds